Search - tctmd.com

Displaying 461 - 480 of 687

Sort: Relevancy | Date

News Industry News

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

October 20, 2015

News Conference News TCT 2015

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Industry News

Study From China Examines Clinical Outcomes Of Two Drug-Eluting Stents With Bioresorbable Polymers Employing Different Elution And Absorption Rates

October 14, 2015

News Industry News

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

October 14, 2015

News Industry News

Plaque Modification With Scoring Balloon Improves Angiographic Outcomes In Patients Treated With A Drug-Coated Balloon For Drug-Eluting Stent Restenosis

October 14, 2015

News Conference News TCT 2015

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

October 14, 2015

News Conference News TCT 2015

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

October 14, 2015

News Conference News TCT 2015

IN.PACT SFA: Benefits of DCB Persist at 2 Years

October 14, 2015

News Industry News

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

October 14, 2015

News Conference News TCT 2015

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

October 13, 2015

News Conference News TCT 2015

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

October 13, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

News Conference News TCT 2015

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

October 12, 2015

News Industry News

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

Advertisement

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Study From China Examines Clinical Outcomes Of Two Drug-Eluting Stents With Bioresorbable Polymers Employing Different Elution And Absorption Rates

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

Plaque Modification With Scoring Balloon Improves Angiographic Outcomes In Patients Treated With A Drug-Coated Balloon For Drug-Eluting Stent Restenosis

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

IN.PACT SFA: Benefits of DCB Persist at 2 Years

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

SORT-OUT VI: 3-Year Outcomes Similar With BES, ZES

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content